Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy

FDG PET-CT in Non-small Cell Lung Cancer: Relationship between Primary Tumor FDG Uptake and Extensional or Metastatic Potential

“…To our knowledge, there have been no published randomized clinical trials regarding the topic that increased metabolic activity of primary tumor suggested to achieve better survival until now. Despite the measurement of SUVmax in the PET imaging affected by several factors, it remains that increased metabolic activity (SUVmax) of primary tumors has been repetitively shown a negative effect on the prognosis of NSCLC (Xu et al, 2008;Agarwal et al, 2010;Paesmans et al, 2010;Zhang et al, 2011). Worsening of prognosis in NSCLC with a high SUVmax may be partly due to an increase of local extension, and nodal or distant organ metastasis as demonstrated in our study.…”

Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?

“…There is also more limited evidence that the level of uptake on pretreatment scans, as measured by various standardized uptake value (SUV) parameters, may be predictive (11)(12)(13)(14), but results conflict as to whether high or low SUVs are predictive depending on treatment modality (13,14).…”

Assessment of Response to Therapy

“…The percentage change of pretreatment and mid-treatment SUV max was significantly different in responders compared to nonresponders (62 vs 34 %). In this report, the 1-year survival rates of the responders and nonresponders were 68.0 % and 38.1 %, respectively (Zhang et al 2010). Similarly, it has been reported that a reduction of more than 20 % in SUV max at week 3 is associated with longer progression-free survival (de Langen et al 2011).…”